Integrated Report

Full Report

For viewing (PDF/11,899KB)

For printing (PDF/11,899KB)

By Section

• Profile
• On the Publication of the Integrated Report 2021（PDF/238KB)
• History of Value Creation and Growth（PDF/113KB)
• Corporate Mission / Corporate Culture（PDF/44KB)
• Main Products（PDF/116KB)
• Financial and Non-Financial Highlights（PDF/65KB)

• Value Creation Strategies
• Changes in the Environment Surrounding Pharmaceutical Companies / Opportunities and Risks（PDF/85KB)
• Business Model（PDF/295KB)
• Message from the President（PDF/313KB)
• CSR-Based Management and Materiality（PDF/68KB)
• Mid-term Business Plan（PDF/80KB)

• Practice & Performance
• Mid-term Business Plan 2022
• Basic Policy I
  Establishment of growth engine（PDF/1,220KB)
• Strategy 1 Enhance innovation base with new approaches to drug discovery
• Strategy 2 Deliver the highest performance of clinical development
• Message from the CSO
• Strategy 3 Pipeline expansion through strategic investment
• Strategy 4 Regional strategy centering in Japan, North America and China
• Strategy 5 Launch frontier business
• Basic Policy II
  Building of flexible and efficient organization（PDF/198KB)
• Flexible and efficient organization and operations
• Corporate culture and talent to drive innovation
• Message from the Executive Officer in charge of human resources
• Digital transformation
• Message from the CDO
• Environment / Contribution to Societies（PDF/495KB)

• Governance
• Message from the Chairman（PDF/230KB)
• Corporate Governance（PDF/1,755KB)
• Board Members and Executive Officers（PDF/605KB)
• Directors / Audit & Supervisory Board Members
• Executive Officers

• Corporate & Financial Information
• Financial Section（PDF/1,226KB)
• Ten-Year Summary of Selected Financial Data
• Financial Policy (Message from the President)
• Operating Results and Financial Condition, and Business Risks
• Consolidated Financial Statements
• Notes to Consolidated Financial Statements
• Independent Auditor's Report
• Value Chain Initiatives（PDF/359KB)
• Basic Knowledge of Pharmaceuticals（PDF/150KB)
• Corporate Profile / Shareholder Data（PDF/155KB)
• External Evaluations（PDF/148KB)